ClinicalTrials.gg
Not yet recruitingNCT07844551Updated Sep 28, 2026

ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC

A Phase 2 interventional study of Becotatug Vedotin (MRG003) and Pucotenlimab in Stage IVB Oral Cavity Squamous Cell Carcinoma and Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, sponsored by Huashan Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Huashan Hospital · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck — 15 open to participants now, 15 under way, 2 of them phase 3. becotatug vedotin · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
11th of 16
40 · median 52
Started
2026
with 11 others
Phase 2
13 of 16
12 open now
Primary completion
2028-10
later than 11 of 14 live
Registered
15th of 16
by date
Lead sponsor
1 of 16
Huashan Hospital

Among the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, this one is the 11th largest by planned enrollment, is one of 12 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 11 of the 14 other live ones, and was the 15th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

15 of the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for downstaging primary stage IVB oral squamous cell carcinoma or HPV16-negative oropharyngeal squamous cell carcinoma.

Read the detailed description

More than 60% of patients with head and neck squamous cell carcinoma (HNSCC) have locally advanced disease at initial diagnosis, often presenting with a large primary tumor accompanied by marked local invasion and/or regional lymph-node metastasis. In patients with clinical stage IVB oral squamous cell carcinoma (OSCC), tumors frequently invade the masticator space, pterygoid plates, or skull base and/or encase the internal carotid artery; and in patients with clinical stage IVB oropharyngeal squamous cell carcinoma (OPSCC), tumors frequently invade the lateral pterygoid muscle, pterygoid plates, lateral nasopharyngeal wall, or skull base, or encase the carotid artery. Because of extensive infiltration and involvement of critical anatomical structures, radical surgery faces two major challenges in this population: firstly, R0 resection is difficult to achieve, resulting in rapid postoperative recurrence; secondly, radical surgery inevitably causes disfiguring tissue defects and severe functional loss, leading to extremely poor quality of life. The 1- to 2-year overall survival rate for these patients ranges from 22% to 35%.

For the patients with unresectable primary stage IVB OSCC or human papillomavirus (HPV)-negative OPSCC, current standard treatment consists of platinum-based concurrent chemoradiotherapy or radiotherapy following platinum-based induction chemotherapy. Although these regimens are widely used, their efficacy remains unsatisfactory. In recent years, additional approaches have been developed and evaluated, including monoclonal antibodies targeting epidermal growth factor receptor (EGFR), novel radiotherapy fractionation schedules, and induction or neoadjuvant chemotherapy regimens; however, none has demonstrated a clear improvement over standard concurrent chemoradiotherapy. Standard concurrent chemoradiotherapy may also cause toxicities such as late-onset dysphagia and severe xerostomia. Accordingly, developing new therapeutic strategies to improve outcomes in this population has become a major focus in the field of HNSCC.

Neoadjuvant therapy refers to antitumor treatment administered before surgery with the aims of reducing tumor volume, increasing the likelihood of surgical resection, and decreasing the risk of postoperative recurrence; it may therefore improve outcomes in locally advanced malignancies. Given the close interaction between antibody-drug conjugate (ADC) and the host immune system, the combination of these two modalities may theoretically produce synergistic antitumor effects and improve treatment outcomes. Therefore, this prospective, exploratory, two-arm, randomized controlled clinical trial will compare becotatug vedotin, an EGFR-targeted ADC, plus pucotenlimab, an anti-PD-1 monoclonal antibody, with current standard therapy consisting of platinum-based induction chemotherapy or chemoradiotherapy. The investigational regimen is expected to induce deep tumor regression in patients with unresectable primary stage IVB OSCC/OPSCC, achieve tumor downstaging, convert unresectable lesions into lesions amenable to R0 resection, and allow evaluation of efficacy and safety, including potential survival benefits. The study may provide a new therapeutic strategy for patients with stage IVB HNSCC.

03

Conditions studied

  • Stage IVB Oral Cavity Squamous Cell Carcinoma
  • Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Keywords

  • Combination of immunotherapy and antibody-drug conjugate
  • Stage IVB OSCC or OPSCC
  • Induction conversion
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status: 0-1;
  2. Histopathologically confirmed oral/oropharyngeal squamous cell carcinoma, including tumors of the tongue, gingiva, buccal mucosa, floor of mouth, hard palate, retromolar trigone, base of tongue, soft palate, or parapharyngeal region;
  3. Clinical stage IVB (cT1-4N3M0 or cT4bN0-3M0, AJCC 8th edition);
  4. At least one measurable target lesion according to (RECIST) version 1.1;
  5. Complete blood count: white blood cell count >3,000/mm3, >8 g/L, and count >80,000/mm3;
  6. Hepatic function: /aspartate aminotransferase (ALT/AST) \<2.5 times the (ULN), and \<1.5 times the ULN;
  7. Renal function: serum creatinine \<1.5 times the ULN;
  8. Positive expression (combined positive score [CPS] >=1) and positive EGFR expression (immunohistochemistry [IHC] 2+ or 3+);
  9. Written provided.

Exclusion criteria

Exclusion Criteria:

  1. Unresolved toxicity of grade 2 or higher due to prior anticancer therapy;
  2. Known grade 3-4 reaction to any study treatment;
  3. Active severe clinical infection (>grade 2 infection according to version 5.0);
  4. Uncontrolled hypertension or active cardiovascular disease, including cerebrovascular accident within 6 months before randomization, myocardial infarction within 6 months before randomization, unstable angina, congestive heart failure of (NYHA; Appendix 5) class II or higher, or a serious arrhythmia that cannot be controlled with medication or may potentially affect study treatment;
  5. Active disease requiring systemic immunomodulatory or therapy for a chronic condition (e.g., disease-modifying drugs, glucocorticoids, or ). Replacement therapy, such as thyroxine, insulin, or physiologic glucocorticoid replacement for adrenal or pituitary insufficiency, is not considered systemic therapy;
  6. History of another and its treatment;
  7. History of radiotherapy to the maxillofacial and neck region;
  8. HPV-positive oropharyngeal cancer;
  9. Pregnant or breastfeeding women;
  10. Known history of (HIV) infection, or uncontrolled active , defined as hepatitis B surface antigen (HBsAg) positivity together with a detectable hepatitis B virus DNA (HBV-DNA) copy number above the of the local laboratory at the study center;
  11. Participation in another clinical study within 30 days before enrollment;
  12. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Combination therapy of immunotherapy and antibody-drug conjugate. Drugs: Becotatug vedotin: 2.3 mg/kg by intravenous infusion once every 21 days. Pucotenlimab: 200 mg by intravenous infusion once every 21 days. Each treatment cycle is 21 days, and two cycles will be administered. On each dosing day, pucotenlimab will be infused first, followed by becotatug vedotin.

    Drug: Becotatug Vedotin (MRG003) · Drug: Pucotenlimab

  • Active comparator
    Control Arm

    Participants in the control arm will undergo MDT assessment by the investigators and receive a platinum-based induction chemotherapy regimen. Cisplatin: 75mg/m2 by intravenous infusion once every 21 days. Each treatment cycle is 21 days, and two cycles will be administered. All required assessments must be completed within 3 days before dosing. Treatment may continue only after the safety evaluation is satisfactory.

    Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical downstaging rate

    The ratio of patients could achieve clinical downstaging after two cycles of drug treatment according to the AJCC 8th edition.

    Time frame: 6 months

Secondary outcomes

  1. Surgical R0 resection rate

    The ratio of R0 resection, complete removal of all grossly visible tumor with no residual tumor cells at the microscopic resection margins, i.e., microscopically negative margins.

    Time frame: 6 months

  2. Rate of 2-year overall survival

    Overall survival is calculated from the date of randomization to death. The rate of 2-year overall survival is reported as the percentage of patients who are overall survival for 2 years from the date of randomization.

    Time frame: 2 years

  3. Rate of 2-year progression free survival

    Progression free survival is calculated from the date of randomization to local tumor recurrence or progression, locoregional recurrence or progression, distant metastasis, or death. The rate of 2-year progression free survival is reported as the percentage of patients who are progression free survival for 2 years from the date of randomization.

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — After the completion of the trial.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 2 years after completion of the trial, for 6 months.

Access criteria: Access to IPD data can be obtained upon scientifically sound request from the study PI, who will contact the Clinical Research Unit, Huashan Hospital, Fudan University. Access will be released after the approval from the Clinical Research Unit.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 24 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Oct 30, 2028
CompletionEst.
Dec 30, 2030
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844551
Lead sponsor
Huashan Hospital
Responsible party
Lai-ping Zhong (Professor, Huashan Hospital) — Principal investigator
First posted
Sep 28, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Oct 30, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Sep 28, 2026

Study contacts

Lai-ping Zhong, MD, PhD
Contact
zhonglp@hotmail.com
+862152888915
Ying-ying Huang, MD, PhD
Contact
kqyxyhyy@163.com
+862152889999 ext. 7182
Lai-ping Zhong
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug vedotin

Start the discussion